Navigation Links
First images from medical beamline at Canadian Light Source
Date:12/23/2008

y or invisible to conventional X-ray radiographs and mammograms. For example, the mouse's lungs are clearly visible in the DEI image, but only appear as a faint blur in the conventional absorption image.

DEI imaging is proving to be a valuable tool in visualizing cancer, imaging bone cartilage and understanding the structure and function of reproductive organs. Other techniques planned for development at BMIT include the delivery of precise beams of high energy X-rays for the treatment of cancer.


'/>"/>

Contact: Matthew Dalzell
matthew.dalzell@lightsource.ca
306-657-3739
Canadian Light Source, Inc.
Source:Eurekalert  

0

GOOD

Page: 1 2

Related biology news :

1. Study first to pinpoint why analgesic drugs may be less potent in females than in males
2. Singapore research team first place in Brain-Computer Interface contest
3. First trimester smoking linked to oral clefts
4. More freedom to take risks: DFG funds the first Reinhart Koselleck Projects
5. First fuel-handling facility in the Galapagos earns environmental certification
6. First-ever socioeconomic study on coral reefs points to challenges of coastal resource management
7. Caltech researchers get first look at how groups of cells coordinate their movements
8. Childrens National convenes first childhood obesity symposium
9. Missouri Botanical Garden publishes first catalogue of plants of the Southern Cone
10. First comprehensive inventory of life in Antarctica
11. First trial in patients with a potential treatment of the incurable ALS muscle disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
First images from medical beamline at Canadian Light Source
First images from medical beamline at Canadian Light Source
Breaking Biology Technology:RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4